HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data
Rhea-AI Summary
Recursion (NASDAQ: RXRX) has partnered with HealthVerity to enhance its clinical trial capabilities through real-world data integration. The collaboration will give Recursion access to de-identified data covering over 340M lives in the US, which will be integrated into their Recursion OS platform.
This strategic partnership aims to improve clinical trial design, patient population insights, and trial feasibility assessments. Recursion will leverage HealthVerity's comprehensive healthcare data ecosystem to enhance their AI-driven approach, predict patient responses, and optimize study designs while ensuring regulatory compliance.
The integration of HealthVerity's real-world data into Recursion's platforms is expected to streamline clinical development, reduce costs, and accelerate the development of novel therapeutics while maintaining HIPAA compliance and patient privacy standards.
Positive
- Access to extensive healthcare data covering 340M lives enhances clinical trial capabilities
- Integration with Recursion OS platform could reduce clinical development costs
- Partnership enables improved trial design and patient recruitment efficiency
- Enhanced ability to predict patient responses and optimize study designs
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, RXRX declined 5.67%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Through this agreement, Recursion will integrate HealthVerity de-identified data for over 340M covered lives within the US into its advanced data science and machine learning platforms, the Recursion OS, allowing for deeper insights into patient populations, enhanced trial design and feasibility assessments, as well as clinical operations workflows. By leveraging these high-quality, linked data assets, Recursion seeks to industrialize clinical development, reduce costs, and accelerate the development of novel therapeutics.
"Our partnership with Recursion underscores the transformative potential of real-world data in driving smarter clinical trials," said Andrew Kress, CEO of HealthVerity. "By providing seamless access to the industry's most comprehensive and interoperable real-world data, we empower innovators like Recursion to make data-driven decisions that streamline clinical development."
Recursion's proprietary AI-driven approach relies on integrating diverse datasets and AI/ML models to identify novel insights into human biology and molecule design. The incorporation of real-world data from HealthVerity Marketplace will further strengthen Recursion's ability to predict patient responses, refine study designs, and ensure clinical trial sites are positioned to meet enrollment goals.
"With the majority of the industry's time and resources focused on clinical trials, we see a significant opportunity to transform how clinical development is designed and executed," said Najat Khan, PhD, Chief R&D Officer and Chief Commercial Officer at Recursion. "By integrating privacy-compliant real-world data from HealthVerity into Recursion OS, we are advancing our mission to optimize trial design through in silico simulations, accelerate recruitment through a patient-centric approach that includes underserved populations, and generate stronger evidence to inform development and regulatory decisions. By doing so, we are not only streamlining clinical development but also ensuring that we bring more impactful, life-changing treatments to patients faster and more efficiently"
The HealthVerity approach to real-world data acquisition and governance ensures compliance with HIPAA and other regulatory frameworks while maintaining the highest standards of patient privacy. By combining data from the nation's largest healthcare data ecosystem, HealthVerity enables precise patient journey insights, supporting clinical development, regulatory submissions, and post-market studies.
For more information, visit www.healthverity.com.
About HealthVerity
HealthVerity is the leader in privacy-protected real-world data exchange, transforming how healthcare and life sciences organizations connect and analyze disparate patient data. By enabling access to the industry's largest RWD ecosystem, HealthVerity supports critical applications in clinical development, commercial strategy, and regulatory decision-making.
About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world's largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology, and chemistry to advance the future of medicine.
Media Contact:
HealthVerity
info@healthverity.com
Recursion
media@recursion.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/healthverity-partners-with-recursion-to-enhance-clinical-trial-analytics-with-real-world-data-302429759.html
SOURCE HealthVerity, Inc.
FAQ
What is the scope of HealthVerity's data access provided to Recursion (RXRX)?
How will Recursion (RXRX) use HealthVerity's real-world data in clinical trials?
What are the expected benefits of the Recursion-HealthVerity partnership for RXRX's clinical development?
How does the HealthVerity partnership enhance Recursion's (RXRX) existing technology platform?
